Standard & Poor’s has affirmed its ‘A-‘ counterparty credit and financial strength ratings and negative outlook on Amedex Insurance Co.
Standard & Poor’s subsequently withdrew the ratings at the company’s request. The ratings reflected Amedex’s good business position as a niche provider of major medical products in Latin America, favorable operating performance, and strong capitalization.
These positive factors are offset by Amedex’s limited size, declining enrollment trends, new business risk through Amedex Bermuda, and high operating expenses, which are the direct consequence of its target market and high level of service provided.
Was this article valuable?
Here are more articles you may enjoy.
Roblox Settles With States for $35.8 Million Over Child Safety
Adjusters: Why the Indemnification Clause Should Stay Top of Mind
Zantac Suits Tossed by Delaware Judge for Flawed Cancer Link
Iran Says Hormuz Strait Now Completely Open for Commercial Ships